LifeVantage lowers outlook amid GLP-1 headwinds. The nutrition company signaled fiscal 2026 results near the low end of guidance, reflecting revenue pressures from competitive GLP-1 weight loss drugs impacting consumer spending. Despite the challenging backdrop, LifeVantage raised its quarterly dividend by 11 percent to $0.05 per share, demonstrating management confidence in cash generation. The company also completed a Shopify platform upgrade and appointed new leadership. While the dividend increase signals stability, the low-end guidance projection suggests management expects continued near-term revenue challenges as market dynamics shift toward pharmaceutical weight loss solutions competing with traditional nutrition products.
Post from MarketNews_en
Log in to interact with content.